Bevacizumab-containing treatment for relapsed or refractory Wilms tumor.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2024-09-01 Epub Date: 2024-07-23 DOI:10.1080/14737140.2024.2381537

Sarah Al-Jilaihawi, Filippo Spreafico, Annelies Mavinkurve-Groothuis, Jarno Drost, Daniela Perotti, Christa Koenig, Jesper Brok

{"title":"Bevacizumab-containing treatment for relapsed or refractory Wilms tumor.","authors":"Sarah Al-Jilaihawi, Filippo Spreafico, Annelies Mavinkurve-Groothuis, Jarno Drost, Daniela Perotti, Christa Koenig, Jesper Brok","doi":"10.1080/14737140.2024.2381537","DOIUrl":null,"url":null,"abstract":"Introduction: Angiogenesis is critical for tumor growth and metastasis. Bevacizumab is an antiangiogenic drug used to treat various adult and childhood solid tumors. Its potential efficacy in Wilms tumor (WT) with poor prognosis is not established.Areas covered: The response to bevacizumab-containing regimens in relapsed or refractory WT was reviewed in available literature. Searches were conducted using PubMed, Scopus, and ClinicalTrials.gov databases. Eight papers were identified, published between 2007 and 2020, including six treatment regimens, predominantly vincristine, irinotecan, and bevacizumab (VIB) ± temozolomide (VITB). Among 16 evaluable patients, there were two complete responses, seven partial responses, five patients achieved stable disease (SD), and two patients had progressive disease. Objective responses (OR) were observed in 56% of all cases. OR or SD was observed in 89% (8/9) patients who received VIB/VITB. Bevacizumab was generally well tolerated. Related toxicities included hypertension, proteinuria, and delayed wound healing.Expert opinion: This review suggests potential effectiveness and good tolerability of bevacizumab in the setting of relapsed/refractory WT when used in combination with other drugs. Such combination therapies may serve as a bridging treatment option to other interventions and more personalized treatment options in the future; however, focused trials are needed to obtain additional evidence.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"837-843"},"PeriodicalIF":2.9000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2381537","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Angiogenesis is critical for tumor growth and metastasis. Bevacizumab is an antiangiogenic drug used to treat various adult and childhood solid tumors. Its potential efficacy in Wilms tumor (WT) with poor prognosis is not established.

Areas covered: The response to bevacizumab-containing regimens in relapsed or refractory WT was reviewed in available literature. Searches were conducted using PubMed, Scopus, and ClinicalTrials.gov databases. Eight papers were identified, published between 2007 and 2020, including six treatment regimens, predominantly vincristine, irinotecan, and bevacizumab (VIB) ± temozolomide (VITB). Among 16 evaluable patients, there were two complete responses, seven partial responses, five patients achieved stable disease (SD), and two patients had progressive disease. Objective responses (OR) were observed in 56% of all cases. OR or SD was observed in 89% (8/9) patients who received VIB/VITB. Bevacizumab was generally well tolerated. Related toxicities included hypertension, proteinuria, and delayed wound healing.

Expert opinion: This review suggests potential effectiveness and good tolerability of bevacizumab in the setting of relapsed/refractory WT when used in combination with other drugs. Such combination therapies may serve as a bridging treatment option to other interventions and more personalized treatment options in the future; however, focused trials are needed to obtain additional evidence.

查看原文本刊更多论文

贝伐单抗--用于治疗复发性或反浸润性疣。

导言血管生成是肿瘤生长和转移的关键。贝伐单抗是一种抗血管生成药物，用于治疗各种成人和儿童实体瘤。它对预后不良的威尔姆斯肿瘤（WT）的潜在疗效尚未确定：对现有文献中复发或难治性WT对含贝伐单抗方案的反应进行了回顾。使用 Pubmed、Scopus 和 ClinicalTrials.gov 数据库进行了检索。共发现8篇发表于2007年至2020年间的论文，包括6种治疗方案，主要是长春新碱、伊立替康和贝伐珠单抗（VIB）±替莫唑胺（VITB）。在 16 例可评估的患者中，有 2 例完全应答、7 例部分应答、5 例病情稳定 (SD)、2 例病情进展。在所有病例中，56%观察到客观反应（OR）。接受 VIB/VITB 治疗的患者中，89%（8/9）观察到 OR 或 SD。贝伐单抗的耐受性普遍良好。相关毒性包括高血压、蛋白尿和伤口愈合延迟：本综述表明，贝伐珠单抗与其他药物联合使用时，在复发/难治性 WT 的治疗中具有潜在的有效性和良好的耐受性。这种联合疗法可作为一种过渡性治疗方案，在未来用于其他干预措施和更个性化的治疗方案，但仍需进行重点试验以获得更多证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.